24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuticals
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
19:48
Israel inks multi-billion-shekel deal to replenish Arrow 3 stocks
15:24
Gigi Levy-Weiss: “Funds that used to visit Israel every month haven’t been here for a year and a half”
14:55
Full list of Israeli high-tech funding rounds in 2024
14:51
FIZE Medical raises $14 million to tackle critical patient care
More stories
Buzz
Most popular
Daily
Weekly
1
Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?
2
$41B in exits: Why Israeli cyber startups are a global powerhouse
3
Israeli fintech Morning acquired for $150 million by Italy's TeamSystem
4
Kaltura exploring sale or merger at $400-$500M valuation
5
Coralogix acquires Aporia in $50M deal to boost AI system transparency
More news
Pharmaceuticals
20 stories about Pharmaceuticals
Rivals' Earning Reports Should Have Teva's Shareholders Worried
05.08.19
|
Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
Teva to Pay California $69 Million in Narcolepsy Drug Settlement
30.07.19
|
Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
Paving the Way to Alzheimer’s Cure, One Algorithm at a Time
19.07.19
|
Tzipi Smilovitz
Israeli scientist Shahar Barbash is making waves in the pharmaceutical world with a new approach to image analysis that has even chemistry Nobel laureate Michael Levitt on board
Pi Therapeutics Raises $19.7 Million
29.05.19
|
Hagar Ravet
Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition
28.05.19
|
Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants
16.05.19
|
Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company
12.05.19
|
Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI
02.05.19
|
Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement
16.04.19
|
CTech
Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
Can-Fite BioPharma to Raise $3.2 Million in Direct Offering
04.04.19
|
CTech
The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
Teva Makes Headway in European Copaxone Patent Case
01.04.19
|
Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
Life Science Investment Firm Pontifax Raises $170 Million Fund
22.11.18
|
Meir Orbach
The firm’s new fund, its sixth, will focus on credit loans to pharmaceutical companies planning to go public
Biotech Company Polypid Raises $15 Million
07.11.18
|
Lilach Baumer
Israel-based Polypid develops encapsulating drug delivery technology that enables extended and localized release in the body
Former Teva Executives Raise $60 Million for Metabolic Disorders Venture
28.10.18
|
Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva
China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite
07.08.18
|
Amarelle Wenkert
New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
Teva Trending Down Following Underwhelming Second Quarter Revenues
02.08.18
|
Dror Reich
On Thursday, the generic drugmaker announced revenues that fell slightly short of analyst consensus
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Oral Insulin Capsule Developer Oramed Raises $18 Million in Direct Offering
10.07.18
|
CTech
Jerusalem-headquartered Oramed intends to use the recent proceeds for research and development and for clinical trials
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18
|
Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Cost-Cutting at CureTech Following Cancellation of Acquisition Deal with Insight
05.07.18
|
CTech
The deal was announced in March, but intended buyer InSight backed out
Previous Articles
More Articles
Please ensure Javascript is enabled for purposes of
website accessibility